Baseline Physiology Studies in Carriers of Gene Variant X Conferring Major Risk of CVD-prone Metabolic Disorders

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

July 31, 2013

Study Completion Date

November 30, 2014

Conditions
HyperlipidemiaDiabetes MellitusMetabolic SyndromeArterial HypertensionObesity
Interventions
OTHER

first phase insulin secretion (FPIR), Hyperinsulinemic euglycemic clamp (HEC), glucose tracer, and palmitate tracer

"FPIR: intravenous infusion of 20 % glucose 0.3 mg/kg in 2 minutes followed by blood sampling at times 0, 2, 4, 6, 8, and 10. Duration 10 minutes.~HEC: intravenous infusion of actrapid 1mU/kg/minute, simultaneous infusion of 20 % glucose at variable rate to reach plasma blood glucose level of 5 mmol/L. Duration 120 minutes~Glucose tracer: bolus of 3H3glucose (12µCi) followed by infusion of 3H3glucose (0,12 µCi/min). Duration 120 minutes.~Palmitate tracer:\[9,10-3H\]-palmitate 0,3 µCi/min. Duration 60 minutes."

Trial Locations (1)

8000

Medicinsk forskningslaboratorium, Aarhus Universitet, Aarhus

All Listed Sponsors
collaborator

Lundbeck Foundation

OTHER

collaborator

Aarhus University Hospital

OTHER

collaborator

Vejle Hospital

OTHER

collaborator

Esbjerg Hospital - University Hospital of Southern Denmark

OTHER

collaborator

Steno Diabetes Center Copenhagen

OTHER

collaborator

University of Copenhagen

OTHER

lead

University of Aarhus

OTHER

NCT01571609 - Baseline Physiology Studies in Carriers of Gene Variant X Conferring Major Risk of CVD-prone Metabolic Disorders | Biotech Hunter | Biotech Hunter